Targeting tissue angiotensin-converting enzyme for imaging cardiopulmonary fibrosis

Current Cardiology Reports

Volumn 10, Issue 2, 2008, Pages 128-134

  Aras, Omer ^a   Dilsizian, Vasken ^b  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BLEOMYCIN; CAPTOPRIL; CARBOXYPEPTIDASE; CHYMASE; CHYMASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUORINE 18; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; LOSARTAN; N [1 BENZYL 2,3 DIOXO 6 (2 PYRIDYLOXY)HEXYL] 2 (5 FORMYLAMINO 1,6 DIHYDRO 6 OXO 2 PHENYL 1 PYRIMIDINYL)ACETAMIDE; TECHNETIUM 99M; VALSARTAN; ANGIOTENSIN RECEPTOR; ANTINEOPLASTIC ANTIBIOTIC;

ANTIOXIDANT ACTIVITY; CARDIOMYOPATHY; CARDIOPULMONARY FIBROSIS; CELL GROWTH; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MODEL; DRUG BINDING; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME LOCALIZATION; EX VIVO STUDY; FIBROBLAST; GENETIC POLYMORPHISM; HEART MUSCLE FIBROSIS; HORMONE SYNTHESIS; HUMAN; IMAGING SYSTEM; LUNG FIBROSIS; MOLECULAR IMAGING; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION; ANIMAL; CHEMICALLY INDUCED DISORDER; DIAGNOSTIC PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; FIBROSIS; GENE EXPRESSION REGULATION; HEART; HEART MUSCLE; METABOLISM; PATHOLOGY;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; CARBOXYPEPTIDASES; CHYMASES; FIBROSIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEART; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MYOCARDIUM; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; PULMONARY FIBROSIS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 44449165530     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-008-0022-4     Document Type: Review

References (65)

1. Cohn JN, Ferrari R, Sharpe N: Cardiac remodeling - concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000, 35:569-582.
2. Harada K, Sugaya T, Murakami K, et al.: Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 1999, 100:2093-2099.
3. Dilsizian V, Eckelman WC, Loredo ML, et al.: Evidence for tissue angiotensin-converting enzyme in explanted hearts of ischemic cardiomyopathy using targeted radiotracer technique. J Nucl Med 2007, 48:182-187.
4. Aras O, Messina SA, Shirani J, et al.: The role and regulation of cardiac angiotensin-converting enzyme for noninvasive molecular imaging in heart failure. Curr Cardiol Rep 2007, 9:150-158.
5. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators [no authors listed]. N Engl J Med 1992, 327:685-691.
6. Riordan JF: Angiotensin-I-converting enzyme and its relatives. Genome Biol 2003, 4:225.
7. Cohen EP, Molteni A, Hill P, et al.: Captopril preserves function and ultrastructure in experimental radiation nephropathy. Lab Invest 1996, 75:349-360.
8. Aras O, Fernia FJ, Maresca AM, et al.: Tc-99-labeled Lisinopril Analogs for Molecular Imaging of ACE Expression in Rats. Paper presented at the 90th Scientific Assembly and Annual Meeting, Radiological Society of North America. Chicago, IL; November 26-December 1, 2006.
9. Sime PJ, O'Reilly KM: Fibrosis of Nhe lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol 2001, 99:308-319.
10. Thannickal VJ, Toews GB, White ES, et al.: Mechanisms of pulmonary fibrosis. Annu Rev Med 2004, 55:395-417.
11. Geiser T: Idiopathic pulmonary fibrosis - a disorder of alveolar wound repair? Swiss Med Wkly 2003, 133:405-411.
12. Dacic S, Yousem SA: Histologic classification of idiopathic chronic interstitial pneumonias. Am J Respir Cell Mol Biol 2003, 29:S5-S9.
13. Wynn TA: Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004, 4:583-594.
14. Eddy AA: Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996, 7:2495-2508.
15. Lakatos HF, Thatcher TH, Kottmann RM, et al.: The role of PPARs in lung fibrosis. PPAR Res 2007, 2007:71323.
16. American Thoracic Society. Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS) [no authors listed]. Am J Respir Crit Care Med 2000, 161:646-664.
17. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001 [no authors listed]. Am J Respir Crit Care Med 2002, 165:277-304.
18. Marshall RP, Gohlke P, Chambers RC, et al.: Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol 2004, 286:L156-L164.
19. Wang R, Alam G, Zagariya A, et al.: Apoptosis of lung epithelial cells in response to TNF-alpha requires angiotensin II generation de novo. J Cell Physiol 2000, 185:253-259.
20. Chen FP, Gong LK, Zhang L, et al.: Early lung injury contributes to lung fibrosis via AT1 receptor in rats. Acta Pharmacol Sin 2007, 28:227-237.
21. Molteni A, Moulder JE, Cohen EF, et al.: Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Biol 2000, 76:523-532.
22. Igic R, Behnia R: Properties and distribution of angiotensin I converting enzyme. Curr Pharm Des 2003, 9:697-706.
23. Marshall RP: The pulmonary renin-angiotensin system. Curr Pharm Des 2003, 9:715-722.
24. Matucci-Cerinic M, Pignone A, Lotti T, et al.: Reduced angiotensin converting enzyme plasma activity in scleroderma. A marker of endothelial injury? J Rheumatol 1990, 17:328-330.
25. Der SS, Huentelman MJ, Stewart J, et al.: ACE2: A novel therapeutic target for cardiovascular diseases. Prog Biophys Mol Biol 2006, 91:163-198.
26. Danilczyk U, Eriksson U, Oudit GY, et al.: Physiological roles of angiotensin-converting enzyme 2. Cell Mol Life Sci 2004, 61:2714-2719.
27. Ferrario CM, Trask AJ, Jessup JA: Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 2005, 289:H2281-H2290.
28. Imai Y, Kuba K, Rao S, et al.: Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005, 436:112-116.
29. Crackower MA, Sarao R, Oudit GY, et al.: Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002, 417:822-828.
30. Kuba K, Imai Y, Penninger JM: Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol 2006, 6:271-276.
31. Hamming I, Cooper ME, Haagmans BL, et al.: The emerging role of ACE2 in physiology and disease. J Pathol 2007, 212:1-11.
32. Wang R, Zagariya A, Ang E, et al.: Fas-induced apoptosis of alveolar epithelial cells requires ANG II generation and receptor interaction. Am J Physiol 1999, 277:L1245-L1250.
33. Bullock GR, Steyaert I, Bilbe G, et al.: Distribution of type-1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease. Histochem Cell Biol 2001, 115:117-124.
34. Marshall RP, McAnulty RJ, Laurent GJ: Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am J Respir Crit Care Med 2000, 161:1999-2004.
35. Wang R, Zagariya A, Ibarra-Sunga O, et al.: Angiotensin II induces apoptosis in human and rat alveolar epithelial cells. Am J Physiol 1999, 276:L885-L889.
36. Uhal BD, Gidea C, Bargout R, et al.: Captopril inhibits apoptosis in human lung epithelial cells: A potential antifibrotic mechanism. Am J Physiol 1998, 275:L1013-L1017.
37. Dostal DE, Rothblum KN, Conrad KM, et al.: Detection of angiotensin I and II in cultured rat cardiac myocytes and fibroblasts. Am J Physiol 1992, 263:C851-C863.
38. Wang R, Ibarra-Sunga O, Verlinski L, et al.: Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol 2000, 279:L143-L151.
39. Robbins ME, Diz DI: Pathogenic role of the renin-angiotensin system in modulating radiation-induced late effects. Int J Radiat Oncol Biol Phys 2006, 64:6-12.
40. Gibbons GH, Pratt RE, Dzau VJ: Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992, 90:456-461.
41. McKay S, de Jongste JC, Saxena PR, et al.: Angiotensin II induces hypertrophy of human airway smooth muscle cells: Expression of transcription factors and transforming growth factor-beta1. Am J Respir Cell Mol Biol 1998, 18:823-833.
42. Gauldie J, Sime PJ, Xing Z, et al.: Transforming growth factor-beta gene transfer to the lung induces myofibroblast presence and pulmonary fibrosis. Curr Top Pathol 1999, 93:35-45.
43. Noble PW: Idiopathic pulmonary fibrosis. New insights into classification and pathogenesis usher in a new era therapeutic approaches. Am J Respir Cell Mol Biol 2003, 29:S27-S31.
44. Sime PJ, Xing Z, Graham FL, et al.: Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997, 100:768-776.
45. Zhao Y, Geverd DA: Regulation of Smad3 expression in bleomycin-induced pulmonary fibrosis: A negative feedback loop of TGF-beta signaling. Biochem Biophys Res Commun 2002, 294:319-323.
46. Sun Y, Zhang JQ, Zhang J, et al.: Cardiac remodeling by fibrous tissue after infarction in rats. J Lab Clin Med 2000, 135:316-323.
47. Mezzano SA, Ruiz-Ortega M, Egido J: Angiotensin II and renal fibrosis. Hypertension 2001, 38:635-638.
48. Yoshiji H, Kuriyama S, Yoshii J, et al.: Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001, 34:745-750.
49. Chen K, Wei Y, Sharp GC, et al.: Inhibition of TGFbeta1 by anti-TGFbeta1 antibody or lisinopril reduces thyroid fibrosis in granulomatous experimental autoimmune thyroiditis. J Immunol 2002, 169:6530-6538.
50. Ghazi-Khansari M, Mohammadi-Karakani A, Sotoudeh M, et al.: Antifibrotic effect of captopril and enalapril on paraquat-induced lung fibrosis in rats. J Appl Toxicol 2007, 27:342-349.
51. Molteni A, Ward WF, Ts'ao CH, et al.: Monocrotaline-induced cardiopulmonary damage in rats: Amelioration by the angiotensin-converting enzyme inhibitor CL242817. Proc Soc Exp Biol Med 1986, 182:483-493.
52. Punithavathi D, Venkatesan N, Babu M: Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. Br J Pharmacol 2000, 131:169-172.
53. Ali SM, Laping NJ, Fredrickson TA, et al.: Angiotensin-converting enzyme inhibition attenuates proteinuria and renal TGF-beta 1 mRNA expression in rats with chronic renal disease. Pharmacology 1998, 57:20-27.
54. He X, Han B, Mura M, et al.: Angiotensin-converting enzyme inhibitor captopril prevents oleic acid-induced severe acute lung injury in rats. Shock 2007, 28:106-111.
55. Nadrous HF, Ryu JH, Douglas WW, et al.: Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest 2004, 126:438-446.
56. Day RM, Yang Y, Suzuki YJ, et al.: Bleomycin upregulates gene expression of angiotensin-converting enzyme via mitogen-activated protein kinase and early growth response 1 transcription factor. Am J Respir Cell Mol Biol 2001, 25:613-619.
57. Venkatesan N, Punithavathi D, Chandrakasan G: Biochemical and connective tissue changes in cyclophosphamide-induced lung fibrosis in rats. Biochem Pharmacol 1998, 56:895-904.
58. Li X, Rayford H, Uhal BD: Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice. Am J Pathol 2003, 163:2523-2530.
59. Tomimori Y, Muto T, Saito K, et al.: Involvement of mast cell chymase in bleomycin-induced pulmonary fibrosis in mice. Eur J Pharmacol 2003, 478:179-185.
60. Sakaguchi M, Takai S, Jin D, et al.: A specific chymase inhibitor, NK3201, suppresses bleomycin-induced pulmonary fibrosis in hamsters. Eur J Pharmacol 2004, 493:173-176.
61. Tiret L, Rigat B, Visvikis S, et al.: Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992, 51:197-205.
62. Andersson B, Blange I, Sylven C: Angiotensin-II type 1 receptor gene polymorphism and long-term survival in patients with idiopathic congestive heart failure. Eur J Heart Fail 1999, 1:363-369.
63. Cicoira M, Zanolla L, Rossi A, et al.: Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 2001, 37:1808-1812.
64. Sharma P, Smith I, Maguire G, et al.: Clinical value of ACE genotyping in diagnosis of sarcoidosis. Lancet 1997, 349:1602-1603.
65. Adamzik M, Frey U, Sixt S, et al.: ACE I/D but not AGT (-6)A/G polymorphism is a risk factor for mortality in ARDS. Eur Respir J 2007, 29:482-488.